Back to Journals » Lung Cancer: Targets and Therapy » Volume 2

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer

Authors Takeda, Okamoto I, Nishimura, Kazuhiko N 

Published 14 October 2011 Volume 2011:2 Pages 59—67


Review by Single anonymous peer review

Peer reviewer comments 2

Masayuki Takeda1, Isamu Okamoto1, Yasumasa Nishimura2, Kazuhiko Nakagawa1
1Department of Medical Oncology, 2Department of Radiation Oncology, Kinki University Faculty of Medicine, Osaka, Japan

Abstract: The epidermal growth factor receptor (EGFR) is a promising therapeutic target in non-small cell lung cancer, and several therapeutic agents that target this receptor, including EGFR tyrosine kinase inhibitors and monoclonal antibodies to EGFR, have been developed. Such monoclonal antibodies have shown efficacy in combination with chemotherapy and radiotherapy. Nimotuzumab (h-R3) is a humanized monoclonal antibody to EGFR, and its effects in combination with radiation have been sufficiently promising to warrant further investigation in several types of cancer. Furthermore, the typical severe dermatologic toxicities associated with other monoclonal antibodies to EGFR have not been observed with nimotuzumab. We here summarize the results of preclinical studies as well as of previous and ongoing clinical trials of nimotuzumab for the treatment of non-small cell lung cancer.

Keywords: non-small cell lung cancer, epidermal growth factor receptor, antibody

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.